Drug data last refreshed 11h ago · AI intelligence enriched 1w ago
VIDEX EC is an oral delayed-release capsule formulation of didanosine, a nucleoside reverse transcriptase inhibitor (NRTI) approved in 2000 for HIV treatment. The drug works by inhibiting HIV reverse transcriptase, reducing viral replication in patients with HIV infection. It represents a foundational antiretroviral therapy from the early era of combination ART.
With LOE approaching and moderate competitive pressure (score: 30), the brand team is likely in defensive/transition mode with minimal growth investments and reduced headcount planning.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on VIDEX EC offers limited career growth; this is a legacy product in managed decline with minimal new hiring and shrinking market opportunity. Career value lies in mastering mature product portfolio management, specialty channel dynamics, or supporting transition to generic/biosimilar landscapes rather than innovation or scale.
Worked on VIDEX EC at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.